Omeprazol Slavia (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Slavia, is a proton pump inhibitor presented as oral tablets for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal disorders such as gastro‑esophageal reflux disease, peptic ulcer disease, and Zollinger‑Ellison syndrome.

GNH USA supplies Omeprazol Slavia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory compliance.

Omeprazol Slavia, a proton pump inhibitor, is indicated for several acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): reduces esophageal acid exposure and promotes healing of erosive esophagitis. - Peptic ulcer disease: facilitates ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumors.

Omeprazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Abdominal pain - Diarrhea - Nausea - Flatulence - Constipation

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reactions - Angioedema - Clostridioides difficile infection - Hypomagnesemia (low magnesium levels) - Osteoporotic fractures with long‑term use - Elevated liver enzymes - Interstitial nephritis

When using Omeprazol Slavia, several precautions should be observed to ensure safe therapy.

- Assess renal function: adjust use in patients with severe renal impairment. - Evaluate hepatic function: use with caution in severe liver disease. - Monitor for infection: prolonged therapy may increase risk of C. difficile infection. - Review concomitant medications: potential interactions with antiplatelet agents and others. - Avoid long‑term use without supervision: increased risk of bone fractures and nutrient deficiencies. - Store at ambient temperature: keep in the original pack, protect from moisture.

Omeprazole can alter the pharmacokinetics of several co‑administered medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of the antiviral. - High‑dose methotrexate: increased toxicity. - HIV protease inhibitors (e.g., ritonavir): altered plasma levels.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum concentrations. - Diazepam: enhanced sedation. - Iron salts: reduced iron absorption.